It's probably a smaller amount than you would have expected.
With rumors of a white knight swirling, the following three cannabis stocks may make perfect suitors.
These income stocks look incredibly secure for a long time to come.
Derivative cannabis products will soon hit licensed Canadian dispensaries.
Rapid sales growth yields no guarantee of profitability in the cannabis space.
Bitcoin may be hot now, but the future for the world's largest cryptocurrency isn't so bright.
This high-growth and budding industry comes with one must-know warning.
A lengthy new study pinpoints the age at which a majority of retirees would get the most out of Social Security.
Curaleaf's $875 million deal to buy Grassroots shakes up the multistate dispensary leaderboard.
A little-known Social Security rule can turn regret into opportunity under the right circumstances.
Despite promises of an expedited review, CBD-focused investors could be disappointed with the Food and Drug Administration's findings.
In this instance, a bigger payout isn't something to cheer.
The cannabis industry is evolving, and so must investor perceptions of the businesses within the industry.
At 21% and 10%, respectively, these ultra-high-yield payouts are running on borrowed time.
All three of these smaller marijuana stocks is capable of at least 300,000 kilos of annual cannabis output.
These drug developers are all valued at less than four times this year's projected earnings per share.
Canopy CFO Mike Lee dishes on growth expectations for fiscal 2020.
OrganiGram remains on track to complete its Moncton campus by year's end, and is eagerly awaiting the launch of derivative cannabis products in December.
The buzz is beginning to wear off for the most popular cannabis stocks.
These brand-name behemoths are head and shoulders above their dividend-paying competition.